Antivenom Dosing Algorithm

ورودی‌های بالینی بیمار

حداقل ۱ — حداکثر ۳۰۰ • واحد: kg

پنل نتیجه و تصمیم بالینی
در انتظار ورودی‌ها
initial dose vials
—vials
آماده برای ارزیابی

پارامترهای بالینی بیمار را در فرم روبرو وارد کنید و روی «محاسبه» کلیک نمایید تا نمره، طبقه خطر و اقدامات فوری نمایش داده شوند.

طبقات خطر و بازه‌های امتیاز:
  • No Treatment0–0
  • Standard Initial Dose4–6
  • Higher Initial Dose6–12
Direct Clinical Answer

The Antivenom Dosing Algorithm calculates assessing acute poisoning severity, antidote indications, and fatal toxicity trajectory. Key inputs include signs of envenomation. Scores guide administering specific antidote therapy, gastrointestinal decontamination, and continuous telemetry monitoring. This standardized assessment improves clinical decision safety and bedside patient management.

Clinical Guidelines & Evidence

Doses antivenom (CroFab only, not Anavip) for pit viper snakebites. This unified treatment algorithm assists with quick identification and management of patients who may benefit from treatment with Crotalidae Polyvalent Immune Fab (CroFab®).

Clinical Indication

The Antivenom Dosing Algorithm is indicated for bedside clinical practice to support Doses antivenom (CroFab only, not Anavip) for pit viper snakebites. This unified treatment algorithm assists with quick identification and management of patients who may benefit from treatment with Crotalidae Polyvalent Immune Fab (CroFab®).. It assists healthcare providers in standardizing clinical assessment and therapeutic decision-making.

Target Population

Target population comprises Patients presenting with acute pharmaceutical overdose, agricultural pesticide ingestion, toxic gas inhalation, or venomous envenomation. Clinical application is indicated across Poison control centers, acute toxicology wards, emergency resuscitation rooms, and intensive care.

Limitations & Contraindications

Initial serum concentrations for sustained-release or co-ingested anticholinergic agents may falsely appear low before delayed absorption peaks. Clinical exclusion: For CroFab administration only - do not use for Anavip dosing.

Clinical Pearls & Action Plan

Rapid clinical toxidrome identification guides immediate antidote administration; do not wait for confirmatory toxicology assays.

Formula & Variables:

Algorithm-based dosing: Initial dose 4-6 vials (up to 12 for severe cases), additional 4-6 vials if control not achieved, maintenance 2 vials q6h x 3 doses

Input Parameters

NameTypeRequiredDescription
signs_of_envenomationstringYesPresence of signs of envenomation including swelling, tenderness, redness, ecchymosis, or blebs at bite site; elevated protime, decreased fibrinogen or platelets; systemic signs (hypotension, bleeding beyond puncture site, refractory vomiting, diarrhea, angioedema, neurotoxicity)
severity_gradestringYesClinical severity grade of envenomation based on local, systemic, and hematologic effects
patient_weight_kgfloatYesPatient weight in kilograms (dosing is same for adults and pediatrics)(kg)

Score Interpretation & Guidance

RangeStageDescription
0–0No TreatmentNo antivenom needed
4–6Standard Initial DoseStandard initial antivenom dose
6–12Higher Initial DoseHigher initial antivenom dose for severe cases

Evidence-Based References (EBM)

  • Lavonas EJ, Ruha AM, Banner W, et al. Unified treatment algorithm for the management of crotaline snakebite in the United States: results of an evidence-informed consensus workshop. BMC Emerg Med. 2011;11:2. doi: 10.1186/1471-227X-11-2DOI: 10.1186/1471-227X-11-2
  • Dart RC, Seifert SA, Boyer LV, et al. A randomized multicenter trial of crotalinae polyvalent immune Fab (ovine) antivenom for the treatment for crotaline snakebite in the United States. Arch Intern Med. 2001;161(16):2030-2036.
  • CroFab® Prescribing Information. BTG International Inc.; August 2018.

Related calculators